Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00268476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Sep 2024 to Mar 2026Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 12200 to confirmed 11992 · Site details revised at 120 of 120 sitesv64Show 3 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Enrollment target: estimated 12200 to confirmed 11992
Site details revised at 120 of 120 sites
MinorSecondary endpoints: details revised at 1 of 13 entriesv63
NotableEnrollment target: 5000 to 8100Study sites: 116 to 120 · Interventions: Radiotherapy to the prostate (Radiation), abiraterone (Drug), celecoxib (Drug), docetaxel (Drug), orchiectomy (Procedure), prednisolone… to ADT (Drug), Radiotherapy to the prostate (Radiation), abiraterone (Drug), celecoxib (Drug), docetaxel (Drug), enzalutamide (Drug)… · Eligibility criteria expanded, about 70 words · 3 morev53Show 6 more changesShow less
Study sites: 116 to 120
Interventions: Radiotherapy to the prostate (Radiation), abiraterone (Drug), celecoxib (Drug), docetaxel (Drug), orchiectomy (Procedure), prednisolone… to ADT (Drug), Radiotherapy to the prostate (Radiation), abiraterone (Drug), celecoxib (Drug), docetaxel (Drug), enzalutamide (Drug)…
NotableLead sponsor: Dominic Hague to Medical Research Councilv51
NotableLead sponsor: Medical Research Council to Dominic HaguePrimary endpoint revised · Enrollment target: 3300 to 4000 · Study sites: 95 to 107 · 7 morev50Show 10 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate cancer is currently managed, either by adding new treatments to the standard approach or by modifying the type of hormone therapy aiming to improve quality-of-life by reducing the side effects of treatment. Each new treatment approach is compared against a control arm receiving the current standard treatments. We aim to identify treatment strategies that enable men to live longer, or as long but with an improved quality-of-life, as well as offering value for money for the health service.
Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate cancer and some results are now already known. More than 10,000 men will join the trial with answers becoming available throughout the trial. New patients joining the trial from Protocol version 17.0 onwards (activated in December 2018) may be eligible to join one of two treatment comparisons, metformin (treatment group K; the "metformin comparison") and transdermal oestradiol (treatment group L; the "transdermal oestradiol comparison"). A computer program will be used to allocate which treatment each participant receives, using a chance process.
Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups currently open to recruitment (June 2017)
1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE will investigate whether adding metformin to the current standard-of-care for non-diabetic men can improve all-cause survival.
2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which has been shown to suppress testosterone as effectively as standard ADT and avoid some of the side-effects. It may also help to avoid the adverse metabolic effects and fatigue and therefore improve overall quality of life compared with standard forms of ADT. STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as current standard forms of ADT.
3. Control group (Arm A): Patients allocated to this group receive the current standard-of-care ADT +/- RT +/- docetaxel.